These results suggest synergistic VISTA, CTLA4, and PD1blockade can enhance antitumor immunity, suppress tumor growth by enhancing CD4+and CD8+ TILs in the TME and overcome immune checkpoints inhibitory resistances. This evidence concerns the gene CTLA4 and neoplasm.